Standard BioTools CFO Withholds 12,739 Shares to Cover RSU Taxes

Rhea-AI Filing Summary

Standard BioTools (LAB) Chief Financial Officer Hanjoon Alex Kim reported a disposition of 12,739 shares of common stock on 08/20/2025 at a price of $1.27 per share. The Form 4 shows the shares were withheld to satisfy tax withholding obligations arising from restricted stock units that vested from grants made on May 20, 2024 and March 21, 2025. After the reported disposition, the reporting person beneficially owns 2,427,825 shares. The filing was signed by an attorney-in-fact on behalf of Mr. Kim on 08/22/2025.

Positive

• Transaction was a tax-withholding action tied to RSU vesting rather than an open-market sale
• Filing includes clear explanation referencing the original RSU grants and prior Form 4s
• Reporting person remains a significant holder with 2,427,825 shares after the transaction

Negative

• 12,739 shares were disposed, reducing the reporting person’s holdings
• Price per share reported is $1.27, which may reflect valuation at time of withholding

Insights

Financial Analyst

TL;DR: Insider sold a small block of shares via tax-withholding upon RSU vesting; no cash-sale trading indicated.

The Form 4 discloses a disposition of 12,739 shares executed as a tax-withholding action tied to RSU vesting. The transaction price is reported at $1.27 per share, and it reduced the reporting person’s beneficial holdings to 2,427,825 shares. Because the filing specifies withholding to satisfy tax obligations rather than an open-market sale, this is a routine administrative action following equity compensation events.

Corporate Governance Expert

TL;DR: Administrative withholding for vested RSUs was used; form is properly executed and explains the withholding reason.

The disclosure clearly identifies the withheld shares as satisfying tax withholding from RSUs granted on May 20, 2024 and March 21, 2025, with prior Form 4 filings referenced for those grants. Signature by attorney-in-fact is included with date. From a governance and disclosure perspective, the filing meets the required description of transaction nature and origin.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Hanjoon Alex

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		F		12,739(1)	D	$1.27	2,427,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively.

	/s/ Hanjoon Alex Kim by Tomone Tanaka, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Standard BioTools (LAB) insider Hanjoon Alex Kim report on Form 4?

The Form 4 reports a disposition of 12,739 shares on 08/20/2025 at $1.27 per share, with the shares withheld to satisfy tax withholding from vested RSUs.

Why were the 12,739 shares disposed by the reporting person?

The filing states the shares were withheld to satisfy tax withholding obligations arising from restricted stock units that vested from grants on May 20, 2024 and March 21, 2025.

How many shares does the reporting person own after the transaction?

After the reported transaction, the reporting person beneficially owns 2,427,825 shares.

Who filed the Form 4 and when was it signed?

The Form 4 reports the transaction by Hanjoon Alex Kim (Chief Financial Officer) and was signed by an attorney-in-fact on 08/22/2025.

Were the RSU grants previously reported?

Yes. The explanation references RSU grants originally reported on Form 4s filed with the SEC on May 21, 2024 and March 24, 2025.